Alpha Crest Capital Management LLC Ironwood Pharmaceuticals Inc Transaction History

Alpha Crest Capital Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $1.33 Million - $1.62 Million	130,780 Added 74.43%	306,494 $3.18 Million
Q2 2022 Aug 11, 2022	BUY	$11.05 - $12.72 $1.58 Million - $1.82 Million	143,071 Added 438.29%	175,714 $2.03 Million
Q1 2022 May 12, 2022	SELL	$10.61 - $12.88 $2.58 Million - $3.13 Million	-243,323 Reduced 88.17%	32,643 $411,000
Q4 2021 Feb 09, 2022	BUY	$10.86 - $13.95 $1.48 Million - $1.9 Million	136,387 Added 97.71%	275,966 $3.22 Million
Q3 2021 Nov 10, 2021	BUY	$11.92 - $13.92 $105,301 - $122,969	8,834 Added 6.76%	139,579 $1.82 Million
Q2 2021 Aug 12, 2021	BUY	$10.16 - $13.11 $176,306 - $227,497	17,353 Added 15.3%	130,745 $1.68 Million
Q1 2021 May 13, 2021	BUY	$9.04 - $11.86 $537,852 - $705,634	59,497 Added 110.39%	113,392 $1.27 Million
Q4 2020 Feb 12, 2021	SELL	$9.05 - $12.2 $70,970 - $95,672	-7,842 Reduced 12.7%	53,895 $614,000
Q3 2020 Nov 12, 2020	SELL	$8.99 - $10.74 $7,605 - $9,086	-846 Reduced 1.35%	61,737 $555,000
Q2 2020 Aug 12, 2020	BUY	$9.14 - $11.97 $73,988 - $96,897	8,095 Added 14.86%	62,583 $646,000
Q1 2020 May 13, 2020	BUY	$8.58 - $14.01 $369,051 - $602,612	43,013 Added 374.84%	54,488 $550,000
Q4 2019 Feb 12, 2020	SELL	$8.22 - $14.0 $106,243 - $180,950	-12,925 Reduced 52.97%	11,475 $153,000
Q3 2019 Nov 12, 2019	BUY	$8.59 - $10.96 $209,596 - $267,424	24,400 New	24,400 $209,000
Q2 2019 Aug 12, 2019	SELL	$9.8 - $12.89 $235,200 - $309,360	-24,000 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$8.27 - $12.73 $198,480 - $305,520	24,000 New	24,000 $325,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.